Role of comprehensive cancer centres during economic and disease transition: National Cancer Centre, Singapore-a case study

The Lancet Oncology

Volumn 9, Issue 8, 2008, Pages 796-802

  Soo, Khee Chee ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CENTER; CANCER INCIDENCE; CASE STUDY; DEVELOPING COUNTRY; ECONOMIC ASPECT; GEOGRAPHY; HEALTH CARE FACILITY; MEDICAL INFORMATICS; MEDICAL SPECIALIST; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; REVIEW; SINGAPORE;

CANCER CARE FACILITIES; DEVELOPING COUNTRIES; FEMALE; FORECASTING; HUMANS; INCIDENCE; MALE; MEDICAL ONCOLOGY; NATIONAL HEALTH PROGRAMS; NEOPLASMS; ONCOLOGY SERVICE, HOSPITAL; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; SINGAPORE; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS;

EID: 47849092080     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70199-2     Document Type: Review

References (23)

1. Boyle P. The globalisation of cancer. Lancet 368 (2006) 629-630
2. Barton M., Frommer M., and Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 7 (2006) 584-595
3. Selby P., Gillis C., and Haward R. Benefits from specialised cancer care. Lancet 348 (1996) 313-318
4. 2007 Singapore Department of Statistics. Indigenous gross national income (at current market prices). Yearbook of statistics Singapore 2007 (August, 2007), Ministry of Trade and Industry, Singapore 74 Point 5.1
5. Tan M., Ooi L., Aw S., and Hui K. Cloning and identification of HDMCP, a novel liver-specific uncoupling protein that is downregulated in human hepatocellular carcinoma. J Biol Chem 279 (2004) 45235-45244
6. Seow A, Koh WP, Chia KS, et al. Trends in cancer incidence in Singapore 1968-2002. Singapore Cancer Registry Report no 6, 2004.
7. Singapore's Review Committee of National Health Policies. Affordable health care-a White Paper. October, 1993.
8. NIH National Institute of Health. The NIH's Director's Panel on Clinical Research Report (2007), Department of Health and Human Services, National Institute of Health, Bethesda, MD
9. Goldstein J., and Brown M. The clinical investigator: bewitched, bothered and bewildered-but still loved. J Clin Invest 99 (1997) 2803-2812
10. Pober J., Neuhauser C., and Pober J. Obstacles facing translational research in academic medical centres. FASEB J 15 (2001) 2303-2313
11. Rosenberg L. The physician-scientist: an essential and fragile link in the medical research chain. J Clin Invest 103 (1999) 1621-1626
12. Thong P., Ong K., Goh N., et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 8 (2007) 950-952
13. Loong S., Kong H., and Price A. Reduced DNA-dependent protein kinase activity in two cell lines derived from adult cancer patients with radionecrosis. Oncogene 23 (2004) 5562-5566
14. Toh H., Teo M., Ong K., et al. Use of sirolimus for Epstein-Barr-virus-positive smooth muscle tumour. Lancet Oncol 7 (2006) 955-957
15. Poon D., Yap S., Mancer K., Quek S., and Soh L. Induction chemotherapy followed by radiotherapy in Merkel-cell carcinoma. Lancet Oncol 5 (2004) 509-510
16. Wee J., Tan E., Tai B., et al. Randomised phase III trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (2005) 6730-6738
17. Chow P., Tai B., Tan C., et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multi- centre randomised control trial. Hepatology 36 (2002) 1221-1226
18. Soo K., Tan E., Wee J., et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer 93 (2005) 279-286
19. Shepherd F., Pereira J., Ciuleanu T., et al. A randomised phase III trial of erlotinib (Tarceva, OSI774) as second line or third line treatment following chemotherapy in patients with advanced non-small cell lung cancer. A trial of the National Cancer Institute of Canada Clinical Trials Group. N Engl J Med 353 (2005) 123-132
20. Sabapathy K., Hochedlinger K., Nam S., Bauer A., Karin M., and Wagner E. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun dependent cell proliferation. Mol Cell 15 (2004) 713-725
21. Vikhanskaya F., Toh W., Dulloo I., et al. p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat Cell Biol 9 (2007) 698-705
22. Aggarwal A., Leong S., and Lee C. Wavelet transformations of tumor expression profiles reveals a pervasive genome-wide imprinting of aneuploidy on the cancer transcriptome. Cancer Res 65 (2005) 186-194
23. Soo K. Singapore's proposed graduate medical school: an expensive medical tutorial college or an opportunity for transforming Singapore medicine?. Ann Acad Med Singapore 34 (2005) 176-181